2025. Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy. Dermatology Reports. (Jul. 2025). DOI:https://doi.org/10.4081/dr.2025.10315.